A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer-Reference-Cited by-同舟云学术

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer

Published:2021-12-15 Issue:624 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Chung Andrew W.¹²³^ORCID,Anand Kartik³^ORCID,Anselme Ann C.¹²³^ORCID,Chan Alfred A.⁴,Gupta Nakul⁵^ORCID,Venta Luz A.⁵^ORCID,Schwartz Mary R.⁶^ORCID,Qian Wei²³,Xu Yitian²³^ORCID,Zhang Licheng²³^ORCID,Kuhn John⁷,Patel Tejal³⁸,Rodriguez Angel A.⁹^ORCID,Belcheva Anna³,Darcourt Jorge³^ORCID,Ensor Joe³^ORCID,Bernicker Eric³^ORCID,Pan Ping-Ying²³^ORCID,Chen Shu Hsia²³^ORCID,Lee Delphine J.⁴¹⁰^ORCID,Niravath Polly A.³^ORCID,Chang Jenny C.²³^ORCID

Affiliation:

1. Texas A&M University Health Science Center, Bryan, TX 77807, USA.

2. Houston Methodist Research Institute, Houston, TX 77030, USA.

3. Houston Methodist Cancer Center, Houston, TX 77030, USA.

4. Lundquist Institute, Torrance, CA 90502, USA.

5. Department of Radiology, Houston Methodist Hospital, Houston, TX 77030, USA.

6. Houston Methodist Department of Pathology and Genomic Medicine, Houston, TX 77030, USA.

7. University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.

8. Department of General Oncology MD Anderson Cancer Center, Houston, TX 77030, USA.

9. Austin Cancer Center, Austin, TX 78705, USA.

10. David Geffen School of Medicine at Los Angeles, CA 90095, USA.

Abstract

A phase 1/2 clinical trial in patients with chemoresistant triple-negative breast cancer targets the inducible nitric oxide signaling pathway.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference63 articles.

1. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype

2. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

3. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features

4. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling

5. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in angiogenesis and clinical outcome of human gastric cancer

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of nitric oxide synthase/ nitric oxide in infection-related cancers: Beyond antimicrobial activity;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Impact of Molecular Profiling on Therapy Management in Breast Cancer;Journal of Clinical Medicine;2024-08-23

3. Targeting amino acid-metabolizing enzymes for cancer immunotherapy;Frontiers in Immunology;2024-08-14

4. Facile Synthesis of Hemin Derivatives with Modulated Aggregation Behaviour and Enhanced Nitric‐Oxide Scavenging Properties as New Therapeutics for Breast Cancer;Small Science;2024-07-16

5. Targeting ROS in cancer: rationale and strategies;Nature Reviews Drug Discovery;2024-07-09